Tigecycline's Formulation Basics
Tigecycline, a glycylcycline antibiotic sold as Tygacil, is administered intravenously due to poor oral bioavailability. Its formulation includes excipients like hydrochloric acid (for pH adjustment), sodium hydroxide (pH buffer), and mannitol (tonicity agent and bulking agent).[1] These components primarily affect local stability and solubility rather than systemic absorption or elimination, as IV delivery bypasses gut absorption.
Role in Absorption (IV Context)
IV tigecycline achieves 100% bioavailability by direct bloodstream entry, so excipients do not influence gut or first-pass absorption.[2] Mannitol, used at ~50 mg per vial, maintains isotonicity (osmolality ~300 mOsm/kg), preventing infusion-site irritation or hemolysis that could indirectly slow drug uptake into tissues.[1][3] Hydrochloric acid and sodium hydroxide adjust pH to 7.0-8.0, ensuring tigecycline's stability in solution—degradation at extreme pH would reduce effective dosing.[4] No excipients promote active transport or alter blood-tissue partitioning.
Impact on Distribution and Elimination
Excipients have minimal direct effect on elimination. Tigecycline undergoes hepatic metabolism (via glucuronidation) and biliary excretion, with ~59% fecal elimination and 33% renal.[2] Mannitol is renally cleared rapidly but at low doses (~50 mg/vial) does not overload kidneys or compete with tigecycline's clearance (half-life ~27-42 hours).[5] Acid-base excipients stabilize the drug during infusion but do not bind plasma proteins (tigecycline is 71-89% bound) or induce CYP enzymes.[3]
Clinical and Stability Considerations
In stability studies, excipients prevent tigecycline degradation in IV bags (stable up to 24 hours at room temperature).[1] Overdosing mannitol in prolonged infusions could cause osmotic diuresis, mildly accelerating tigecycline's renal clearance fraction, but this is not reported in standard use.[6] No excipient-related pharmacokinetic changes appear in FDA labeling or phase III trials.[2]
Sources
[1] Tygacil Prescribing Information (Pfizer)
[2] FDA Pharmacology Review for Tygacil
[3] DrugPatentWatch.com - Tygacil Formulation Patents
[4] Tigecycline Stability in IV Admixtures (PubMed)
[5] Tigecycline PK/PD Review (Clinical Pharmacology)
[6] Mannitol Excipient Safety in IV Drugs (FDA Guidance)